Post-Congress webinars

Chronic lymphocytic leukemia at ASH21: What’s new?
Romain Guieze
Feb. 10, 2022

Post #ASH21 by the IACH: a focus on MDS
Amer Zeidan
Jan. 27, 2022

Post #ASH21 by the IACH: CAR-T cells
Prof. Bipin Savani
January 19, 2022

Post #ASH21 by the IACH: Hematopoietic Cell Transplantation
Prof. Bipin Savani
January 18, 2022

Myeloma news live from #ASH21 by the IACH – Part 2
Dr. Salomon Manier and Prof. Mohamad Mohty
December 13, 2021

Myeloma news live from #ASH21 by the IACH – Part 1
Dr. Salomon Manier, Prof. Irene Ghobrial and Prof. Mohamad Mohty
December 12, 2021

The IACH post-IMW 2021 Roundtable Discussion
Nizar Bahlis, Luciano Costa, Jean Luc Harousseau, Shaji Kumar, Salomon Manier, María Victoria Mateos, Mohamad Mohty, Cyrille Touzeau, Saad Usmani
October 12, 2021

 
Prof. Mohamad Mohty
July 27, 2021

 

 
Prof. Arnon Nagler

 
Prof. Bipin Savani

 
Prof. Mohamad Mohty

Latest advances in HCT and cellular therapy: a post-TCT summary part II- GVHD, CART and Gene Therapy  
Prof. Bipin Savani

Latest advances in stem cell transplantation and cellular therapy: a post-TCT summary  
Prof. Bipin Savani

Allogeneic Stem Cell Transplantation: an update from ASH 2019
Prof. Arnon Nagler, M.D., M.Sc.

Myeloma update: A flavor of ASH 2019
Mohamad Mohty, MD, PhD

Anti-CD38 monoclonal antibodies in multiple myeloma: a post ASCO/EHA 2019 summary
Mohamad Mohty, MD, PhD

The Myeloma Summary Post ASH 2018
Mohamad Mohty, MD, PhD